Table 6.
TP53 overlapping cluster membership
| Pathway Name, (enrichment p-value) | HPD similarity grouping | de novo Gene Membership | de novo Gene Ontology | de novo Protein Interactants |
|---|---|---|---|---|
| G1 to S cell cycle control (p = 7.30 × 10-3) | ■ | ■ | ■ | ■ |
| G2_PATHWAY (p = 2.58 × 10-3) | ▲ | ▲ | ■ | ■ |
| Class I PI3K signaling events mediated by AKT (p = 0.14) | ● | ▼ | ▲ | ■ |
| DNA damage response (p = 7.20 × 10-3) | ● | ● | ▲ | ■ |
| MAPK signaling pathway (p = 2.88 × 10-2) | ● | ► | ▲ | ■ |
| Glioma (p = 6.70 × 10-3) | ► | ► | ▲ | ■ |
| Non-small cell lung cancer (p = 5.80 × 10-3) | ► | ► | ▲ | ■ |
| Melanoma (p = 7.63 × 10-3) | ► | ► | ▲ | ■ |
| Endometrial Cancer (p = 5.59 × 10-3) | ► | ► | ▲ | ■ |
Note: p-values are derived from one-tail Fisher's Exact test, before multiple test correction. Dividers and matching symbols indicate pathways groups within a consolidation method.